Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levodopa. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.64 |
| ▸ | SLC7A5 | Q01650 | 6/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.82 |
| ▸ | RECQL | P46063 | 4/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.82 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.82 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.82 |
| ▸ | USP2 | O75604 | 3/20 | 0.82 |
| ▸ | LCK | P06239 | 2/20 | 0.82 |
| ▸ | EGFR | P00533 | 1/20 | 0.82 |
| ▸ | FYN | P06241 | 1/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.82 |
| ▸ | HTR2A | P28223 | 1/20 | 0.82 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.64 |
| ▸ | DRD2 | P14416 | 2/20 | 0.64 |
| ▸ | DRD1 | P21728 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levodopa SCHEMBL5494247 | 1.00 | SLC7A5 (0.82) | SLC7A5KDM4ERECQLTDP1ALOX15 | |
| Levodopa SCHEMBL1491625 | 1.00 | SLC7A5 (0.82) | SLC7A5KDM4ERECQLTDP1ALOX15 | |
| Levodopa SCHEMBL5494243 | 1.00 | SLC7A5 (0.82) | SLC7A5KDM4ERECQLTDP1ALOX15 | |
| Levodopa SCHEMBL28992922 | 0.98 | SLC7A5 (0.79) | SLC7A5KDM4ERECQLTDP1ALOX15 | |
| Levodopa SCHEMBL6369139 | 0.94 | SLC7A5 (0.73) | SLC7A5KDM4ERECQLTDP1ALOX15 | |
| Levodopa SCHEMBL29260902 | 0.94 | SLC7A5 (0.73) | SLC7A5KDM4ERECQLTDP1ALOX15 | |
| Phenylalanine SCHEMBL9603018 | 0.93 | SLC7A5 (0.70) | SLC7A5KDM4ERECQLTDP1ALOX15 | |
| Tyrosine SCHEMBL28116186 | 0.93 | SLC7A5 (0.70) | SLC7A5KDM4ERECQLTDP1ALOX15 | |
| Dl-Phenylalanine SCHEMBL20898388 | 0.93 | SLC7A5 (0.70) | SLC7A5KDM4ERECQLTDP1ALOX15 | |
| Levodopa SCHEMBL23849465 | 0.91 | KDM4E (0.68) | SLC7A5KDM4ERECQLTDP1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10632116-B2 | Combinations of serotonin receptor agonists for treatment of movement disorders | CONTERA PHARMA A/S (DK) | 2020-04-28 | — | — | US | claimed |
| CN-108126766-A | A kind of micro-fluidic chip surface hydrophilic method of modifying | 深圳市梅丽纳米孔科技有限公司 | 2018-06-08 | — | — | CN | claimed |
| US-20160054307-A1 | LED ASSAY READER WITH TOUCHSCREEN CONTROL AND BARCODE SAMPLE ID | IMMUNETICS, INC. | 2016-02-25 | — | — | US | claimed |
| WO-2002083877-A1 | PRODUCTION OF TYROSINE HYDROXYLASE POSITIVE NEURONS | STEM CELL THERAPEUTICS INC. (CA) | 2002-10-24 | — | — | WO | claimed |
| US-20240218408-A1 | Methods of Producing Epimerases and Benzylisoquinoline Alkaloids | HERCULES CAPITAL, INC., AS AGENT | 2024-07-04 | — | — | US | disclosed |
| US-20240209403-A1 | METHODS OF PRODUCING MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-06-27 | — | — | US | disclosed |
| US-20240102061-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-03-28 | — | — | US | disclosed |
| US-11884949-B2 | Methods of producing morphinan alkaloids and derivatives | ANTHEIA, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-11859225-B2 | Methods of producing epimerases and benzylisoquinoline alkaloids | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| CN-116964190-A | Method for increasing yields of morphinan alkaloids and derivatives | 安思雅公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-4253525-A2 | METHODS OF PRODUCING EPIMERASES AND BENZYLISOQUINOLINE ALKALOIDS | The Board of Trustees of the Leland Stanford Junior University (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-4247937-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | Antheia, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-0929688-A1 | SUSTAINED DELIVERY DEVICE AND METHODS OF MAKING AND USING THE SAME | Symbiontics, Inc. (US) | 1999-07-21 | — | — | EP | disclosed |
| EP-0871459-A1 | VECTOR AND METHOD OF USE FOR NUCLEIC ACID DELIVERY TO NON-DIVIDING CELLS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1998011245-A1 | SUSTAINED DELIVERY DEVICE AND METHODS OF MAKING AND USING THE SAME | SYMBIONTICS, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1997012622-A1 | VECTOR AND METHOD OF USE FOR NUCLEIC ACID DELIVERY TO NON-DIVIDING CELLS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1997-04-10 | — | — | WO | disclosed |
| US-5082670-A | Genetic engineering, parkinson*s disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1992-01-21 | — | — | US | disclosed |
| EP-0449948-A4 | GRAFTING GENETICALLY MODIFIED CELLS TO TREAT DISEASES OF THE CENTRAL NERVOUS SYSTEM | — | 1991-11-13 | — | — | EP | disclosed |
| EP-0449948-A1 | GRAFTING GENETICALLY MODIFIED CELLS TO TREAT DISEASES OF THE CENTRAL NERVOUS SYSTEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1991-10-09 | — | — | EP | disclosed |
| WO-1990006757-A1 | GRAFTING GENETICALLY MODIFIED CELLS TO TREAT DISEASES OF THE CENTRAL NERVOUS SYSTEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1990-06-28 | — | — | WO | disclosed |